Unlocking the value of pharmaceutical IP assets
In the past decade IP litigation has grown more costly and risky,1 but none more so than pharmaceutical patent litigation. Unlike ordinary IP disputes, the complexity of pharmaceutical patents and associated regulatory hurdles amplify risk. And even if a claiman…
Provide your information below to view this page.
